ALX Oncology (ALXO) Projected to Post Earnings on Thursday

ALX Oncology (NASDAQ:ALXO) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect ALX Oncology to post earnings of ($0.72) per share for the quarter.

ALX Oncology Stock Down 2.9 %

Shares of ALX Oncology stock opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a 50-day moving average of $1.42 and a 200 day moving average of $1.63. The firm has a market cap of $52.74 million, a price-to-earnings ratio of -0.34 and a beta of 0.96. ALX Oncology has a 1 year low of $0.95 and a 1 year high of $17.83.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALXO. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Friday, January 24th. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. UBS Group decreased their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a report on Monday, January 27th. Finally, HC Wainwright decreased their target price on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a report on Friday, January 24th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $3.05.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.